ADT impacts mood of patients with prostate cancer, as perceived by partners
the ONA take:
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer and those negative effects are concurrently observed by their partners, according to a new study published online ahead of print in the journal Psycho-Oncology.
For the study, researchers from Mount Allison University in Sackville, Canada, and the University of British Columbia in Vancouver, Canada, sought to assess the relationship between androgen deprivation therapy and the mood of patients with prostate cancer and their partners.
Researchers enrolled 295 patients and 84 partners. Participants completed an online survey evaluating the patients' current mood and mood prior to therapy, relationship adjustment, and sexual function. Results were compared with that of men who received non-hormonal treatments. Results showed that 82 patients currently treated with androgen deprivation therapy reported worsened mood compared with the 213 not on hormonal therapy. Researchers found that the 42 partners of patients on hormonal therapy reported declines in the patient's mood, but to a greater extent that the patient.
"The psychological changes related to ADT can impact relationships and affect the quality of life of both PCa patients and partners," the authors conclude. "Patients and their partners are likely to benefit from being well informed about the psychological effects of androgen deprivation on men beginning ADT."
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|